BR100 Decreased By (-0.55%)
BR30 Decreased By (-0.86%)
KSE100 Decreased By (-0.47%)
KSE30 Decreased By (-0.6%)
AGHA 6.05 Decreased By ▼ -0.05 (-0.82%)
BECO 3.83 Decreased By ▼ -0.05 (-1.29%)
BML 58.33 Decreased By ▼ -1.66 (-2.77%)
BOP 28.35 Decreased By ▼ -0.31 (-1.08%)
CNERGY 13.64 Decreased By ▼ -0.44 (-3.13%)
CSIL 5.21 Increased By ▲ 0.02 (0.39%)
FCCL 52.28 Decreased By ▼ -0.33 (-0.63%)
FFL 12.90 Decreased By ▼ -0.09 (-0.69%)
FNEL 1.13 Increased By ▲ 0.01 (0.89%)
KEL 5.79 Decreased By ▼ -0.17 (-2.85%)
KOSM 5.51 Increased By ▲ 0.22 (4.16%)
LOTCHEM 23.89 Decreased By ▼ -0.58 (-2.37%)
MLCF 90.51 Decreased By ▼ -0.52 (-0.57%)
NBP 159.72 Decreased By ▼ -2.38 (-1.47%)
NCPL 49.60 Increased By ▲ 0.59 (1.2%)
NPL 51.80 Decreased By ▼ -0.61 (-1.16%)
OGDC 306.78 Increased By ▲ 0.57 (0.19%)
PACE 9.15 Decreased By ▼ -0.10 (-1.08%)
PAEL 32.33 Decreased By ▼ -0.39 (-1.19%)
PIBTL 12.93 Decreased By ▼ -0.15 (-1.15%)
PPL 213.93 Decreased By ▼ -1.59 (-0.74%)
PRL 96.96 Decreased By ▼ -3.85 (-3.82%)
PTC 45.19 Decreased By ▼ -0.83 (-1.8%)
SSGC 22.53 Decreased By ▼ -0.61 (-2.64%)
TBL 9.02 Decreased By ▼ -0.12 (-1.31%)
TELE 6.72 Decreased By ▼ -0.09 (-1.32%)
TPL 25.91 Increased By ▲ 1.15 (4.64%)
TPLP 12.60 Increased By ▲ 0.31 (2.52%)
TREET 23.46 Decreased By ▼ -0.52 (-2.17%)
TRG 51.96 Decreased By ▼ -1.12 (-2.11%)
By

WASHINGTON: The administration of US President Joe Biden announced plans on Thursday to spend $3.2 billion to accelerate the development and discovery of antiviral treatments against Covid-19 and future threats.

The plan is called the Antiviral Program for Pandemics and its funding comes from the American Rescue Plan, a $1.9 trillion package passed by Congress in March.

"Antivirals are an important complement to existing vaccines, especially for individuals with certain conditions that might put them at a greater risk, for those whom vaccines may not be as protective," Anthony Fauci, the president's chief medical advisor on the pandemic, told reporters.

Antiviral medication can also act as an important line of defense against emerging variants of concern that evade the protective action of current generation vaccines, he added.

The plan will help accelerate clinical testing for oral antiviral pills currently under various stages of development, such as Merck's molnupiravir as well as efforts by Pfizer and Atea-Roche.

The plan is for these to be taken very early after an infection is confirmed, in order to stop the disease from progressing to the severe stage - mimicking what Tamiflu does for influenza. The other pillar of the program is seeding the discovery of new antivirals - not just against this coronavirus and its wider family, but other families of viruses that are believed to have pandemic potential.

Comments

Comments are closed for this article.